Basal efflux of bile acids contributes to drug-induced bile acid-dependent hepatocyte toxicity in rat sandwich-cultured hepatocytes

Toxicology in Vitro

Volumn 29, Issue 7, 2015, Pages 1454-1463

  Susukida, Takeshi ^a   Sekine, Shuichi ^a   Ogimura, Eiichiro ^a   Aoki, Shigeki ^a   Oizumi, Kumiko ^a   Horie, Toshiharu ^b   Ito, Kousei ^a  

^a CHIBA UNIVERSITY   (Japan)

^b TEIKYO HEISEI UNIVERSITY   (Japan)

Author keywords

Bile acid; Bile salt export pump; Drug induced liver injury; Multidrug resistance associated protein; Sandwich cultured hepatocyte

Indexed keywords

BILE ACID; BILE SALT EXPORT PUMP; CYCLOSPORIN A; QUINIDINE; TAUROCHOLIC ACID; VERLUKAST; ABC TRANSPORTER; ABCB11 PROTEIN, RAT; ABCC4 PROTEIN, RAT; CYCLOSPORIN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 3; PROPIONIC ACID DERIVATIVE; QUINOLINE DERIVATIVE;

ANIMAL CELL; ARTICLE; BILE ACID METABOLISM; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; INHIBITION KINETICS; LIVER CELL CULTURE; LIVER TOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN ANALYSIS; PROTEIN FUNCTION; RAT; SANDWICH CULTURED HEPATOCYTE; TOXIC HEPATITIS; ANIMAL; CELL CULTURE; CELL CULTURE TECHNIQUE; CHOLESTASIS; HEK293 CELL LINE; LIVER CELL; METABOLISM; SPRAGUE DAWLEY RAT;

RATTUS;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BILE ACIDS AND SALTS; CELL CULTURE TECHNIQUES; CELLS, CULTURED; CHOLESTASIS; CYCLOSPORINE; HEK293 CELLS; HEPATOCYTES; HUMANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PROPIONATES; QUINIDINE; QUINOLINES; RATS, SPRAGUE-DAWLEY;

EID: 84936791987     PISSN: 08872333     EISSN: 18793177     Source Type: Journal    
DOI: 10.1016/j.tiv.2015.06.004     Document Type: Article

References (42)

1. Akita H., Suzuki H., Hirohashi T., Takikawa H., Sugiyama Y. Transport activity of human MRP3 expressed in Sf9 cells: comparative studies with rat MRP3. Pharm. Res. 2002, 19:34-41.
2. Ballatori N., Christian W.V., Lee J.Y., Dawson P.A., Soroka C.J., Boyer J.L., Madejczyk M.S., Li N. OSTalpha-OSTbeta: a major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia. Hepatology 2005, 42:1270-1279.
3. Byrne J.A., Strautnieks S.S., Mieli-Vergani G., Higgins C.F., Linton K.J., Thompson R.J. The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. Gastroenterology 2002, 123:1649-1658.
4. Dawson P.A., Hubbert M., Haywood J., Craddock A.L., Zerangue N., Christian W.V., Ballatori N. The heteromeric organic solute transporter alpha-beta, Ostalpha-Ostbeta, is an ileal basolateral bile acid transporter. J. Biol. Chem. 2005, 280:6960-6968.
5. Dawson S., Stahl S., Paul N., Barber J., Kenna J.G. In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans. Drug Metab. Dispos. 2012, 40:130-138.
6. Di Marco A., Yao D., Laufer R. Demethylation of radiolabelled dextromethorphan in rat microsomes and intact hepatocytes. Eur. J. Biochem. 2003, 270:3768-3777.
7. Fattinger K., Funk C., Pantze M., Weber C., Reichen J., Stieger B., Meier P.J. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin. Pharmacol. Ther. 2001, 69:223-231.
8. Jemnitz K., Veres Z., Vereczkey L. Contribution of high basolateral bile salt efflux to the lack of hepatotoxicity in rat in response to drugs inducing cholestasis in human. Toxicol. Sci. 2010, 115:80-88.
9. Kaplowitz N. Drug-induced liver disorders: implications for drug development and regulation. Drug Saf. 2001, 24:483-490.
10. Keitel V., Burdelski M., Warskulat U., Kuhlkamp T., Keppler D., Haussinger D., Kubitz R. Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis. Hepatology 2005, 41:1160-1172.
11. Kemp D.C., Zamek-Gliszczynski M.J., Brouwer K.L. Xenobiotics inhibit hepatic uptake and biliary excretion of taurocholate in rat hepatocytes. Toxicol. Sci. 2005, 83:207-214.
12. Kock K., Ferslew B.C., Netterberg I., Yang K., Urban T.J., Swaan P.W., Stewart P.W., Brouwer K.L. Risk factors for development of cholestatic drug-induced liver injury: inhibition of hepatic basolateral bile acid transporters multidrug resistance-associated proteins 3 and 4. Drug Metab. Dispos. 2014, 42:665-674.
13. Kostrubsky S.E., Strom S.C., Kalgutkar A.S., Kulkarni S., Atherton J., Mireles R., Feng B., Kubik R., Hanson J., Urda E., Mutlib A.E. Inhibition of hepatobiliary transport as a predictive method for clinical hepatotoxicity of nefazodone. Toxicol. Sci. 2006, 90:451-459.
14. Letschert K., Faulstich H., Keller D., Keppler D. Molecular characterization and inhibition of amanitin uptake into human hepatocytes. Toxicol. Sci. 2006, 91:140-149.
15. Li L., Lee T.K., Meier P.J., Ballatori N. Identification of glutathione as a driving force and leukotriene C4 as a substrate for oatp1, the hepatic sinusoidal organic solute transporter. J. Biol. Chem. 1998, 273:16184-16191.
16. Li L., Meier P.J., Ballatori N. Oatp2 mediates bidirectional organic solute transport: a role for intracellular glutathione. Mol. Pharmacol. 2000, 58:335-340.
17. Liang D., Hagenbuch B., Stieger B., Meier P.J. Parallel decrease of Na(+)-taurocholate cotransport and its encoding mRNA in primary cultures of rat hepatocytes. Hepatology 1993, 18:1162-1166.
18. Meier P.J., Stieger B. Bile salt transporters. Annu. Rev. Physiol. 2002, 64:635-661.
19. Mennone A., Soroka C.J., Cai S.Y., Harry K., Adachi M., Hagey L., Schuetz J.D., Boyer J.L. Mrp4-/- mice have an impaired cytoprotective response in obstructive cholestasis. Hepatology 2006, 43:1013-1021.
20. Morgan R.E., Trauner M., van Staden C.J., Lee P.H., Ramachandran B., Eschenberg M., Afshari C.A., Qualls C.W., Lightfoot-Dunn R., Hamadeh H.K. Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol. Sci. 2010, 118:485-500.
21. Morgan R.E., van Staden C.J., Chen Y., Kalyanaraman N., Kalanzi J., Dunn R.T., Afshari C.A., Hamadeh H.K. A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol. Sci. 2013, 136:216-241.
22. Nakanishi T., Shibue Y., Fukuyama Y., Yoshida K., Fukuda H., Shirasaka Y., Tamai I. Quantitative time-lapse imaging-based analysis of drug-drug interaction mediated by hepatobiliary transporter, multidrug resistance-associated protein 2, in sandwich-cultured rat hepatocytes. Drug Metab. Dispos. 2011, 39:984-991.
23. Ninomiya M., Ito K., Horie T. Functional analysis of dog multidrug resistance-associated protein 2 (Mrp2) in comparison with rat Mrp2. Drug Metab. Dispos. 2005, 33:225-232.
24. Ogimura E., Sekine S., Horie T. Bile salt export pump inhibitors are associated with bile acid-dependent drug-induced toxicity in sandwich-cultured hepatocytes. Biochem. Biophys. Res. Commun. 2011, 416:313-317.
25. Pedersen J.M., Matsson P., Bergstrom C.A., Hoogstraate J., Noren A., LeCluyse E.L., Artursson P. Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol. Sci. 2013, 136:328-343.
26. Rius M., Nies A.T., Hummel-Eisenbeiss J., Jedlitschky G., Keppler D. Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane. Hepatology 2003, 38:374-384.
27. Schuster D., Laggner C., Langer T. Why drugs fail - a study on side effects in new chemical entities. Curr. Pharm. Des. 2005, 11:3545-3559.
28. Seward D.J., Koh A.S., Boyer J.L., Ballatori N. Functional complementation between a novel mammalian polygenic transport complex and an evolutionarily ancient organic solute transporter, OSTalpha-OSTbeta. J. Biol. Chem. 2003, 278:27473-27482.
29. Shitara Y., Itoh T., Sato H., Li A.P., Sugiyama Y. Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J. Pharmacol. Exp. Ther. 2003, 304:610-616.
30. Stieger B., Fattinger K., Madon J., Kullak-Ublick G.A., Meier P.J. Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology 2000, 118:422-430.
31. St-Pierre M.V., Kullak-Ublick G.A., Hagenbuch B., Meier P.J. Transport of bile acids in hepatic and non-hepatic tissues. J. Exp. Biol. 2001, 204:1673-1686.
32. Strautnieks S.S., Bull L.N., Knisely A.S., Kocoshis S.A., Dahl N., Arnell H., Sokal E., Dahan K., Childs S., Ling V., Tanner M.S., Kagalwalla A.F., Nemeth A., Pawlowska J., Baker A., Mieli-Vergani G., Freimer N.B., Gardiner R.M., Thompson R.J. A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat. Genet. 1998, 20:233-238.
33. Swift B., Pfeifer N.D., Brouwer K.L. Sandwich-cultured hepatocytes: an in vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity. Drug Metab. Rev. 2010, 42:446-471.
34. Tchaparian E.H., Houghton J.S., Uyeda C., Grillo M.P., Jin L. Effect of culture time on the basal expression levels of drug transporters in sandwich-cultured primary rat hepatocytes. Drug Metab. Dispos. 2011, 39:2387-2394.
35. Teng S., Piquette-Miller M. Hepatoprotective role of PXR activation and MRP3 in cholic acid-induced cholestasis. Br. J. Pharmacol. 2007, 151:367-376.
36. Vanwijngaerden Y.M., Wauters J., Langouche L., Vander Perre S., Liddle C., Coulter S., Vanderborght S., Roskams T., Wilmer A., Van den Berghe G., Mesotten D. Critical illness evokes elevated circulating bile acids related to altered hepatic transporter and nuclear receptor expression. Hepatology 2011, 54:1741-1752.
37. Wang R., Liu L., Sheps J.A., Forrest D., Hofmann A.F., Hagey L.R., Ling V. Defective canalicular transport and toxicity of dietary ursodeoxycholic acid in the abcb11-/- mouse: transport and gene expression studies. Am. J. Physiol. Gastrointest. Liver Physiol. 2013, 305:G286-G294.
38. Warner D.J., Chen H., Cantin L.D., Kenna J.G., Stahl S., Walker C.L., Noeske T. Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification. Drug Metab. Dispos. 2012, 40:2332-2341.
39. Yamaoka K., Tanigawara Y., Nakagawa T., Uno T. A pharmacokinetic analysis program (multi) for microcomputer. J. Pharmacobiodyn. 1981, 4:879-885.
40. Yang K., Pfeifer N.D., Hardwick R.N., Yue W., Stewart P.W., Brouwer K.L. An experimental approach to evaluate the impact of impaired transport function on hepatobiliary drug disposition using Mrp2-deficient TR- rat sandwich-cultured hepatocytes in combination with Bcrp knockdown. Mol. Pharm. 2014, 11:766-775.
41. Zelcer N., Reid G., Wielinga P., Kuil A., van der Heijden I., Schuetz J.D., Borst P. Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem. J. 2003, 371:361-367.
42. Zollner G., Wagner M., Fickert P., Silbert D., Gumhold J., Zatloukal K., Denk H., Trauner M. Expression of bile acid synthesis and detoxification enzymes and the alternative bile acid efflux pump MRP4 in patients with primary biliary cirrhosis. Liver Int. 2007, 27:920-929.